Mexico healthcare and pharmaceutical markets see significant growth

Mexico’s healthcare and pharmaceutical sectors are experiencing significant growth driven by rising pharmaceutical expenditure, strong import demand, and a shift toward localized production. Germany Trade & Invest estimates the Mexican pharmaceutical market at approximately USD 20 billion in 2026, with projections suggesting it could double by 2033. Data from IQVIA indicates the market is heading toward roughly USD 22.6 billion, with growth increasingly fueled by innovation, pricing, and product mix rather than volume alone.

Simultaneously, the medical device sector is seeing increased opportunities due to Mexico’s aging demographic. With approximately 18 million people aged 60 or older, and projections suggesting one in five residents will reach this age by 2050, there is a rising demand for technologies to manage chronic conditions. Cardiovascular disease and diabetes account for over 63% of family-medicine consultations among the elderly, driving the need for blood-pressure monitors, glucose-management tools, and cardiac devices.